Enanta Pharmaceuticals, Inc. (ENTA)
10.99
-0.48
(-4.18%)
USD |
NASDAQ |
Oct 16, 12:46
Enanta Pharmaceuticals SG&A Expense (TTM) : 37.75M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 37.75M |
| March 31, 2026 | 38.28M |
| December 31, 2025 | 40.10M |
| September 30, 2025 | 43.93M |
| June 30, 2025 | 47.91M |
| March 31, 2025 | 51.33M |
| December 31, 2024 | 54.18M |
| September 30, 2024 | 57.85M |
| June 30, 2024 | 57.96M |
| March 31, 2024 | 57.17M |
| December 31, 2023 | 56.71M |
| September 30, 2023 | 52.89M |
| June 30, 2023 | 51.66M |
| March 31, 2023 | 51.97M |
| December 31, 2022 | 48.67M |
| September 30, 2022 | 45.48M |
| June 30, 2022 | 41.27M |
| March 31, 2022 | 36.82M |
| December 31, 2021 | 34.67M |
| September 30, 2021 | 32.54M |
| June 30, 2021 | 30.91M |
| March 31, 2021 | 29.25M |
| December 31, 2020 | 27.81M |
| September 30, 2020 | 27.36M |
| June 30, 2020 | 26.79M |
| Date | Value |
|---|---|
| March 31, 2020 | 26.12M |
| December 31, 2019 | 26.02M |
| September 30, 2019 | 26.25M |
| June 30, 2019 | 25.91M |
| March 31, 2019 | 25.90M |
| December 31, 2018 | 24.82M |
| September 30, 2018 | 23.44M |
| June 30, 2018 | 22.73M |
| March 31, 2018 | 21.83M |
| December 31, 2017 | 21.58M |
| September 30, 2017 | 20.75M |
| June 30, 2017 | 20.07M |
| March 31, 2017 | 19.12M |
| December 31, 2016 | 18.08M |
| September 30, 2016 | 16.97M |
| June 30, 2016 | 16.22M |
| March 31, 2016 | 15.58M |
| December 31, 2015 | 14.59M |
| September 30, 2015 | 13.54M |
| June 30, 2015 | 12.61M |
| March 31, 2015 | 11.57M |
| December 31, 2014 | 10.70M |
| September 30, 2014 | 10.02M |
| June 30, 2014 | 9.005M |
| March 31, 2014 | 8.19M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Perspective Therapeutics, Inc. | 29.46M |
| Coherus Oncology, Inc. | 92.60M |
| BridgeBio Pharma, Inc. | 645.86M |
| RenovoRx, Inc. | 9.594M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |